New combo therapy targets Tough-to-Treat myeloma

NCT ID NCT06550895

Ongoing Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This early-phase study is testing a combination of two treatments—cilta-cel (a cell therapy) and talquetamab (a drug)—in 11 people with high-risk multiple myeloma that has not responded to prior therapies. The main goal is to check safety and side effects. Researchers will also look at whether the combination helps shrink or control the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ciltacabtagene autoleucel (a cell therapy) and talquetamab (a drug)
What this could lead to: If it works, this could point toward a new treatment option for people with high-risk multiple myeloma who have not responded to other therapies.
What could go wrong: This is a very early, small phase 2 safety study with only 11 participants. The combination may cause serious side effects, and it is not yet known if it will effectively control the disease long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Austin Hospital

Heidelberg, 3084, Australia
Barbara Ann Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States
Norton Cancer Institute

Louisville, Kentucky, 40207, United States
Peter MacCallum Cancer Centre

Melbourne, 3000, Australia
Royal Prince Alfred Hospital

Camperdown, 2050, Australia
The Alfred Hospital

Melbourne, 3004, Australia
University of Iowa Hospital and Clinics

Iowa City, Iowa, 52242, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.